This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl) -5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyri midin-4-yl) methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.本發明涉及二氫嘧啶衍生物的複合物及其在藥物中的應用，具體涉及化合物(S)-4-(((R)-6-(2-氯-4-氟苯基)-5-(甲氧羰基)-2-(噻唑-2-基)-3,6-二氫嘧啶-4-基)甲基)嗎啉-3-甲酸(I)或其互變異構體(Ia)和L-酒石酸所形成的複合物及其藥物組合物，進一步涉及該化合物與L-酒石酸形成的複合物或其藥物組合物在製備藥物中的用途，尤其是在製備用於預防、處理、治療或減輕B型肝炎(HBV)感染的藥物中的用途。
